Zumutor Biologics is betting on a novel cancer drug that activates natural killer cells. With its lead candidate in phase 1 trials, the startup faces the challenge of turning early clinical signals into a licensing deal and investor returns.
Zumutor Biologics is betting on a novel cancer drug that activates natural killer cells. With its lead candidate in phase 1 trials, the startup faces the challenge of turning early clinical signals into a licensing deal and investor returns. by Soban News (international And National News)
